ITP in children: Pathophysiology and current treatment approaches

Journal of Pediatric Hematology/Oncology

Volumn 35, Issue 1, 2013, Pages 1-13

  D'Orazio, John A ^a   Neely, Jessica ^a   Farhoudi, Nina ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

hematology; ITP; splenectomy; thrombocytopenia

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; ELTROMBOPAG; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MERCAPTOPURINE; PREDNISONE; RAPAMYCIN; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; TACROLIMUS; VINCRISTINE;

ABDOMINAL PAIN; BLOOD SMEAR; BONE MARROW BIOPSY; CASE REPORT; CHILD; CHILL; CLINICAL FEATURE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; HEADACHE; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY; IMMUNE THROMBOCYTOPENIA; INCIDENCE; INFUSION RELATED REACTION; LUNG TOXICITY; MEGAKARYOPOIESIS; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIMARY IMMUNE THROMBOCYTOPENIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; SIDE EFFECT; SKIN BRUISING; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS REACTIVATION;

CHILD; HUMANS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

EID: 84871800596     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e318271f457     Document Type: Review

References (105)

1. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190-4207.
2. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Pediatr Clin North Am. 2008;55:393-420.
3. Geddis AE, Balduini CL. Diagnosis of immune thrombocytopenic purpura in children. Curr Opin Hematol. 2007;14: 520-525.
4. Bryant N, Watts R. Thrombocytopenic syndromes masquerading as childhood immune thrombocytopenic purpura. Clin Pediatr (Phila). 2011;50:225-230.
5. Silverman MA. Idiopathic thrombocytopenic purpura. eMedicine Medscape Series. 2011. Available at: http://emedicine.medscape.com/article/779545- overview.
6. Branehog I, Kutti J, Weinfeld A. Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol. 1974;27:127-143.
7. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103: 1364-1369.
8. Diggs LW, Hewlett JS. A study of the bone marrow from 36 patients with idiopathic hemorrhagic, thrombopenic purpura. Blood. 1948;3:1090-1104.
9. Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010. [Epub 2010/04/10] ISSN: 1365-2141 (electronic).
10. Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85: 174-180.
11. Wilson DB. Acquired Platelet Defects. In: Orkin SH, et al, ed. Hematology of Infancy and Childhood. Philadelphia, PA: Saunders Elsevier; 2009:1553-1590.
12. Kuhne T, Imbach P, Bolton-Maggs PH, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358:2122-2125.
13. Kamphuis MM, Oepkes D. Fetal and neonatal alloimmune thrombocytopenia: prenatal interventions. Prenat Diagn. 2011;31:712-719.
14. Skogen B, Killie MK, Kjeldsen-Kragh J, et al. Reconsidering fetal and neonatal alloimmune thrombocytopenia with a focus on screening and prevention. Expert Rev Hematol. 2010;3:559-566.
15. Salama A. Current treatment options for primary immune thrombocytopenia. Expert Rev Hematol. 2011;4:107-118.
16. Pels SG. Current therapies in primary immune thrombocytopenia. Semin Thromb Hemost. 2011;37:621-630.
17. McCrae K. Immune thrombocytopenia: no longer 'idiopathic'. Cleve Clin J Med. 2011;78:358-373.
18. De Mattia D, Del Principe D, Del Vecchio GC, et al. Management of chronic childhood immune thrombocytopenic purpura: AIEOP consensus guidelines. Acta Haematol. 2010;123:96-109.
19. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am. 2010;24:249-273.
20. Imbach P, Kuhne T, Muller D, et al. Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS). Pediatr Blood Cancer. 2006;46:351-356.
21. Kuhne T, Buchanan GR, Zimmerman S, et al. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr. 2003;143:605-608.
22. Halperin DS, Doyle JJ. Is bone marrow examination justified in idiopathic thrombocytopenic purpura? Am J Dis Child. 1988;142:508-511.
23. Calpin C, Dick P, Poon A, et al. Is bone marrow aspiration needed in acute childhood idiopathic thrombocytopenic purpura to rule out leukemia? Arch Pediatr Adolesc Med. 1998;152:345-347.
24. Ahmad Z, Durrani NU, Hazir T. Bone marrow examination in ITP in children: is it mandatory? J Coll Physicians Surg Pak. 2007;17:347-349.
25. Naithani R, Kumar R, Mahapatra M, et al. Is it safe to avoid bone marrow examination in suspected itp? Pediatr Hematol Oncol. 2007;24:205-207.
26. Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386-2393.
27. Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs. 2009; 69:567-576.
28. Fasola G, Fanin R, Masotti A, et al. Long term observation of children with idiopathic thrombocytopenic purpura. Haematologica. 1985;70:419-423.
29. George JN, Woolf SH, Raskob GE. Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. American Society of Hematology. Ann Med. 1998;30:38-44.
30. Nugent DJ. Childhood immune thrombocytopenic purpura. Blood Rev. 2002;16:27-29.
31. Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94:178-184.
32. Medeiros D, Buchanan GR. Idiopathic thrombocytopenic purpura: beyond consensus. Curr Opin Pediatr. 2000;12: 4-9.
33. Bansal D, Bhamare TA, Trehan A, et al. Outcome of chronic idiopathic thrombocytopenic purpura in children. Pediatr Blood Cancer. 2010;54:403-407.
34. Harrington WJ, Minnich V, Hollingsworth JW, et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38:1-10.
35. Schwartz RS. Immune thrombocytopenic purpura - from agony to agonist. N Engl J Med. 2007;357:2299-2301.
36. Tomer A, Koziol J, McMillan R. Autoimmune thrombocytopenia: flow cytometric determination of platelet-associated autoantibodies against platelet-specific receptors. J Thromb Haemost. 2005;3:74-78.
37. Beardsley DS, Spiegel JE, Jacobs MM, et al. Platelet membrane glycoprotein IIIa contains target antigens that bind anti-platelet antibodies in immune thrombocytopenias. J Clin Invest. 1984;74:1701-1707.
38. Curtis BR, McFarland JG, Wu GG, et al. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood. 1994;84:176-183.
39. Ho WL, Lee CC, Chen CJ, et al. Clinical features, prognostic factors, and their relationship with antiplatelet antibodies in children with immune thrombocytopenia. J Pediatr Hematol Oncol. 2012;34:6-12.
40. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood. 2004;103:500-506.
41. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068-4071.
42. Klaassen RJ, Mathias SD, Buchanan G, et al. Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2012;58:395-398.
43. Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24:2767- 2776.
44. McMillan R, Bussel JB, George JN, et al. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83:150-154.
45. Psaila B, Petrovic A, Page LK, et al. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. Blood. 2009;114:4777-4783.
46. Daneshvar DH, Nowinski CJ, McKee AC, et al. The epidemiology of sport-related concussion. Clin Sports Med. 2011;30:1-17.
47. Lincoln AE, Caswell SV, Almquist JL, et al. Trends in concussion incidence in high school sports: a prospective 11- year study. Am J Sports Med. 2011;39:958-963.
48. Marar M, McIlvain NM, Fields SK, et al. Epidemiology of concussions among United States high school athletes in 20 sports. Am J Sports Med. 2012, ISSN: 1552-3365 (electronic).
49. Kuhne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96:1831-1837.
50. Vesely S, Buchanan GR, Cohen A, et al. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol. 2000;22:55-61.
51. Blanchette VS, Hogan VA, McCombie NE, et al. Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura. Transfusion. 1984;24:388-394.
52. Hoemberg M, Stahl D, Schlenke P, et al. The isotype of autoantibodies influences the phagocytosis of antibodycoated platelets in autoimmune thrombocytopenic purpura. Scand J Immunol. 2011;74:489-495.
53. Stasi R. Pathophysiology and therapeutic options in primary immune thrombocytopenia. Blood Transfus. 2011;9: 262-273.
54. Despotovic JM, Lambert MP, Herman JH, et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy. Transfusion. 2011, ISSN: 1537-2995 (electronic).
55. Stefanini M, Perez Santiago E, Chatterjea JB, et al. Corticotropin and cortisone in idiopathic thrombocytopenic purpura. J Am Med Assoc. 1952;149:647-653.
56. Breakey VR, Blanchette VS. Childhood immune thrombocytopenia: a changing therapeutic landscape. Semin Thromb Hemost. 2011;37:745-755.
57. Bader-Meunier B, Proulle V, Trichet C, et al. Misdiagnosis of chronic thrombocytopenia in childhood. J Pediatr Hematol Oncol. 2003;25:548-552.
58. Bredlau AL, Semple JW, Segel GB. Management of immune thrombocytopenic purpura in children: potential role of novel agents. Paediatr Drugs. 2011;13:213-223.
59. Patel K, Berman J, Ferber A, et al. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol. 2001;67:59-60.
60. Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000; 27(6 suppl 12):99-103.
61. Bussel JB. Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. Semin Oncol. 2000;27(6 suppl 12):91-98.
62. Kumar S, Benseler SM, Kirby-Allen M, et al. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics. 2009;123:e159-e163.
63. Cooper N, Evangelista ML, Amadori S, et al. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol. 2007;14:642-646.
64. Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Crit Rev Oncol Hematol. 2008;65:21-31.
65. Heidel F, Lipka DB, von Auer C, et al. Addition of rituximab to standard therapy improves response rate and progressionfree survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost. 2007;97:228-233.
66. Parodi E, Nobili B, Perrotta S, et al. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment. Int J Hematol. 2006;84:48-53.
67. Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107: 2639-2642.
68. Parodi E, Rivetti E, Amendola G, et al. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response. Br J Haematol. 2009;144:552-558.
69. Brah S, Chiche L, Fanciullino R, et al. Efficacy of rituximab in immune thrombocytopenic purpura: a retrospective survey. Ann Hematol. 2012;91:279-285.
70. Grace RF, Bennett CM, Ritchey AK, et al. Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. Pediatr Blood Cancer. 2012;58:221-225.
71. Andersen JC. Response of resistant idiopathic thrombocytopenic purpura to pulsed high-dose dexamethasone therapy. N Engl J Med. 1994;330:1560-1564.
72. Adams DM, Kinney TR, O'Branski-Rupp E, et al. High-dose oral dexamethasone therapy for chronic childhood idiopathic thrombocytopenic purpura. J Pediatr. 1996;128:281-283.
73. Caulier MT, Rose C, Roussel MT, et al. Pulsed highdose dexamethasone in refractory chronic idiopathic thrombocytopenic purpura: a report on 10 cases. Br J Haematol. 1995;91:477-479.
74. Cheng Y, Wong RS, Soo YO, et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med. 2003;349:831-836.
75. Borst F, Keuning JJ, van Hulsteijn H, et al. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol. 2004;83:764-768.
76. Wali YA, Al Lamki Z, Shah W, et al. Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol. 2002;19: 329-335.
77. Hedlund-Treutiger I, Henter JI, Elinder G. Randomized study of IVIg and high-dose dexamethasone therapy for children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2003;25:139-144.
78. Bussel JB, Pinheiro MP. Eltrombopag. Cancer Treat Res. 2011;157:289-303.
79. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118:4338-4345.
80. Kaznelson P. Disappearance of hemorrhagic diathesis of "essential thrombocytopenia" after splenectomy: splenogenic thrombolytic purpura. Wien Klin Wochenschr. 1916;29: 1451-1454. [German].
81. Sandler SG. The spleen and splenectomy in immune (idiopathic) thrombocytopenic purpura. Semin Hematol. 2000;37(1 suppl 1):10-12.
82. Vianelli N, Galli M, de Vivo A, et al. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: longterm results of 402 cases. Haematologica. 2005;90:72-77.
83. Aronis S, Platokouki H, Avgeri M, et al. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr. 2004;93:638-642.
84. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol. 2004;76:143-147.
85. Zarrabi MH, Rosner F. Serious infections in adults following splenectomy for trauma. Arch Intern Med. 1984;144: 1421-1424.
86. Rodeghiero F, Frezzato M, Schiavotto C, et al. Fulminant sepsis in adults splenectomized for idiopathic thrombocytopenic purpura. Haematologica. 1992;77:253-256.
87. Ramsay LE. Letter: infections in asplenic adults. Br Med J. 1974;3:254-255.
88. Hosea SW. Role of the spleen in pneumococcal infection. Lymphology. 1983;16:115-120.
89. Malangoni MA, Dillon LD, Klamer TW, et al. Factors influencing the risk of early and late serious infection in adults after splenectomy for trauma. Surgery. 1984;96:775-783.
90. Castagnola E, Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur J Haematol. 2003;71:319-326.
91. Kessler C, Sandler SG, Bhanji R. Immune thrombocytopenia purpura. eMedicine Medscape Series. 2012, Available at: http://emedicine.medscape.com/ article/202158-overview.
92. Chotivanich K, Udomsangpetch R, McGready R, et al. Central role of the spleen in malaria parasite clearance. J Infect Dis. 2002;185:1538-1541.
93. Slovut DP, Benedetti E, Matas AJ. Babesiosis and hemophagocytic syndrome in an asplenic renal transplant recipient. Transplantation. 1996;62:537-539.
94. Ein SH, Shandling B, Simpson JS, et al. The morbidity and mortality of splenectomy in childhood. Ann Surg. 1977;185: 307-310.
95. Jones P, Leder K, Woolley I, et al. Postsplenectomy infection - strategies for prevention in general practice. Aust Fam Physician. 2010;39:383-386.
96. Bell WR Jr. Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin Hematol. 2000; 37(1 suppl 1):22-25.
97. Rudowski WJ. Accessory spleens: clinical significance with particular reference to the recurrence of idiopathic thrombocytopenic purpura. World J Surg. 1985;9:422-430.
98. Woerner SJ, Abildgaard CF, French BN. Intracranial hemorrhage in children with idiopathic thrombocytopenic purpura. Pediatrics. 1981;67:453-460.
99. Hoots WK, Huntington D, Devine D, et al. Aggressive combination therapy in the successful management of lifethreatening intracranial hemorrhage in a patient with idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol. 1986;8:225-230.
100. Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83:122-125.
101. Salama A, Kiesewetter H, Kalus U, et al. Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia. Thromb Haemost. 2008;100:762-765.
102. Wanachiwanawin W, Piankijagum A, Sindhvananda K, et al. Emergency splenectomy in adult idiopathic thrombocytopenic purpura. A report of seven cases. Arch Intern Med. 1989;149:217-219.
103. Zerella JT, Martin LW, Lampkin BC. Emergency splenectomy for idiopathic thrombocytopenic purpura in children. J Pediatr Surg. 1978;13:243-246.
104. Lightsey AL Jr, McMillan R, Koenig HM. Childhood idiopathic thrombocytopenic purpura. Aggressive management of life-threatening complications. JAMA. 1975;232: 734-736.
105. Puapong D, Terasaki K, Lacerna M, et al. Splenic artery embolization in the management of an acute immune thrombocytopenic purpura-related intracranial hemorrhage. J Pediatr Surg. 2005;40:869-871.